A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

Br J Cancer · 2009 · PMC2743365 · PMID 19690548

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP =0.06so close (0.05 < p ≤ 0.1)

Although the improvement in overall survival did not reach statistical significance ( P =0.06) in the previous report ( Oettle et al , 2007 ), the new CONKO-001 report showed a significant difference in overall survival between the gemcitabine and surgery-only groups after long-term observation (median overall survival, 22.3 months versus 20.2 months; 5-year survival rate, 21.0% versus 9.0%; P =0.005).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.